Please login to the form below

Not currently logged in
Email:
Password:

NICE denies Stelara’s use in psoriatic arthritis

Refuses to extend NHS-recommended indications of Janssen drug
National Institute for Health and Care Excellence NICE logo

Janssen's anti-inflammatory drug Stelara should not be available for NHS use in England and Wales in psoriatic arthritis, according to new guidance.

Cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) issued final guidance recommending against extending use of the drug, which has available to treat the skin disease plaque psoriasis since 2009.

Psoriatic arthritis is a more serious, progressive condition that can lead to severe progressive erosion of the joints. It is associated with psoriasis of the skin or nails.

In its review of Stelara (ustekinumab) in this indication NICE acknowledged the drug was clinically effective compared with conventional treatment with disease-modifying antirheumatic drug (DMARD) therapies.

However, the agency's appraisal committee also concluded that Stelara appeared less effective than already available TNF alpha inhibitors, such as Janssen's Remicade (infliximab), AbbVie's Humira (adalimumab) and Amgen's Enbrel (etanercept). All these drugs are recommended by NICE for use in psoriatic arthritis as part of guidance published in 2010.

Sir Andrew Dillon, NICE chief executive, said: “Whilst recognising the severity of the disease, the Committee concluded that ustekinumab could not be considered a good use of NHS resources.”

These issues were noted in previous negative draft guidance and it appears Janssen and other stakeholders has been unable to overcome the concerns of NICE.

For patients in England and Wales already prescribed Stelara, NICE stated that they have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Article by
Thomas Meek

30th May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Congress Effectiveness Management
Maximising the ROI of scientific meetings...
Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...

Infographics